Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
Saved in:
| Title: | Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO. |
|---|---|
| Authors: | Parmar G; Illawarra Cancer Care Centre, Wollongong Hospital, University of Wollongong, Wollongong, NSW, Australia. gurdeep.parmar@health.nsw.gov.au., Capra M; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil., Seguro F; Hematologia e Hemoterapia do Hospital das Clinicas - FMUSP, São Paulo, Brazil., Hungria V; Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea., Delimpasi S; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos General Hospital, Athens, Greece., Minařík J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic., Špička I; Departments of Medicine and Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Pour L; Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic., Marques H; Department of Hematology, Hospital de Braga, Academic Clinical Center of Braga, Braga, and CINTESIS, Oporto University, Braga, Portugal., Esteves G; Hospital de Santa Maria, Centro de Investigação Clínica, Lisboa, Portugal., Sunami K; Department of Hematology, NHO Okayama Medical Center, Okayama, Japan., Yuda J; Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Hájek R; Department of Haemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Mihályová J; Department of Haemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Soufflet C; Sanofi Research & Development, Vitry-sur-Seine, France., Yu D; Sanofi Research & Development, Cambridge, MA, USA., Benlhassan K; Excelya on Behalf of Sanofi Research & Development, Vitry-sur-Seine, France., Koch V; Excelya on Behalf of Sanofi Research & Development, Vitry-sur-Seine, France., Comerford E; Sanofi Research & Development, Cambridge, MA, USA., Cordero P; Sanofi Research & Development, Reading, UK., Suzan F; Sanofi Research & Development, Vitry-sur-Seine, France., Quach H; Clinical Haematology Service, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Dec 27; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2025 Dec 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
